Ancora Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Ancora Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-23	Closed	-$152	–	1869
2024 Q3	$152	Hold	23	–	–	﹤0.01%	1719
2024 Q2	$172	Hold	23	–	–	﹤0.01%	1759
2024 Q1	$229	Hold	23	–	–	﹤0.01%	1726
2023 Q4	$227	Hold	23	–	–	﹤0.01%	1647
2023 Q3	$176	Buy	+23	New	+$229	﹤0.01%	1702

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Ancora Advisors's RXRX Position: Q4 2024 in Review

Ancora Advisors sold out of Recursion Pharmaceuticals (RXRX) in Q4 2024, closing a stake of 23 shares — an estimated $152 sold.

Ancora Advisors first reported a position in RXRX in Q3 2023 and held it in 5 quarters. The position peaked at $229 in Q1 2024. 316 funds tracked by Wall St. Rank hold RXRX as of Q4 2024.

Ancora Advisors reported no remaining Recursion Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Ancora Advisors sold 23 Recursion Pharmaceuticals shares in Q4 2024, an estimated $152.
Ancora Advisors first reported a position in Recursion Pharmaceuticals in Q3 2023 and held it in 5 quarters.
Ancora Advisors's Recursion Pharmaceuticals position peaked at $229 in Q1 2024.
316 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2024.

Based on Ancora Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.